RETRACTED: Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective: This study was designed to determine the efficacy of ivermectin, an FDA-approved drug, in producing clinical benefits and decreasing the viral load of SARS-CoV-2 among asymptomatic subjects that tested positive for this virus in Lebanon. Methods: A randomized controlled trial was conducted in 100 asymptomatic Lebanese subjects that have tested positive for SARS-CoV2. Fifty patients received standard preventive treatment, mainly supplements, and the experimental group received a single dose (according to body weight) of ivermectin, in addition to the same supplements the control group received. Results: There was no significant difference (p = 0.06) between Ct-values of the two groups before the regimen was started (day zero), indicating that subjects in both groups had similar viral loads. At 72 h after the regimen started, the increase in Ct-values was dramatically higher in the ivermectin than in the control group. In the ivermectin group, Ct increased from 15.13 ± 2.07 (day zero) to 30.14 ± 6.22 (day three; mean ± SD), compared to the control group, where the Ct values increased only from 14.20 ± 2.48 (day zero) to 18.96 ± 3.26 (day three; mean ± SD). Moreover, more subjects in the control group developed clinical symptoms. Three individuals (6%) required hospitalization, compared to the ivermectin group (0%). Conclusion: Ivermectin appears to be efficacious in providing clinical benefits in a randomized treatment of asymptomatic SARS-CoV-2-positive subjects, effectively resulting in fewer symptoms, lower viral load and reduced hospital admissions. However, larger-scale trials are warranted for this conclusion to be further cemented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shakoor, H., Feehan, J., Al Dhaheri, A. S., Ali, H. I., Platat, C., Ismail, L. C., Apostolopoulos, V., & Stojanovska, L. (2021) · Maturitas · doi:10.1016/j.maturitas.2020.08.003 · Cited by 465
Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K., & Abdulamir, A. S. (2020) · doi:10.1101/2020.10.26.20219345 · Cited by 98
Research works printed but not linked: 40
- Lorenz, 2020, Have measures against COVID-19 helped to reduce dengue cases in Brazil?, Travel. Med. Infect. Dis., 37, 101827, 10.1016/j.tmaid.2020.101827 · doi:10.1016/j.tmaid.2020.101827
- Hu, 2021, Characteristics of SARS-CoV-2 and COVID-19, Nat. Rev. Microbiol., 19, 141, 10.1038/s41579-020-00459-7 · DOI · Paper page
- Rabi, F.A., Al Zoubi, M.S., Kasasbeh, G.A., Salameh, D.M., and Al-Nasser, A.D. (2020). SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens, 9. · DOI · Paper page
- Shakkour, Z., Habashy, K.J., Berro, M., Takkoush, S., Abdelhady, S., Koleilat, N., Eid, A.H., Zibara, K., Obeid, M., and Shear, D. (2020). Drug Repurposing in Neurological Disorders: Implications for Neurotherapy in Traumatic Brain Injury. Neuroscientist, 1073858420961078. · DOI
- Hammoud, 2021, Dysregulation of Angiotensin Converting Enzyme 2 Expression and Function in Comorbid Disease Conditions Possibly Contributes to Coronavirus Infectious Disease 2019 Complication Severity, Mol. Pharmacol., 99, 17, 10.1124/molpharm.120.000119 · DOI
- Wehbe, 2020, Molecular Insights Into SARS COV-2 Interaction With Cardiovascular Disease: Role of RAAS and MAPK Signaling, Front. Pharmacol., 11, 836, 10.3389/fphar.2020.00836 · DOI
- Zareef, 2020, COVID-19 in Pediatric Patients: A Focus on CHD Patients, Front. Cardiovasc. Med., 7, 612460, 10.3389/fcvm.2020.612460 · DOI
- Hall, 2020, A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease, Travel. Med. Infect. Dis., 35, 101646, 10.1016/j.tmaid.2020.101646 · DOI · Paper page
- Giordo, R., Zinellu, A., Eid, A.H., and Pintus, G. (2021). Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders. Molecules, 26. · DOI
- Younis, 2020, Hydroxychloroquine in COVID-19 Patients: Pros and Cons, Front. Pharmacol., 11, 597985, 10.3389/fphar.2020.597985 · DOI
- Booz, 2020, Macrophage responses associated with COVID-19: A pharmacological perspective, Eur. J. Pharmacol., 887, 173547, 10.1016/j.ejphar.2020.173547 · DOI
- Kinobe, R.T., and Owens, L. (2021). A systematic review of experimental evidence for antiviral effects of ivermectin and an in-silico analysis of ivermectin’s possible mode of action against SARS-CoV-2. Fundam Clin. Pharmacol. · DOI
- Arévalo, A., Pagotto, R., Pórfido, J., Daghero, H., Segovia, M., Yamasaki, K., Varela, B., Hill, M., Verdes, J., and Duhalde Vega, M. (2020). Ivermectin reduces coronavirus infection in vivo: A mouse experimental model. bioRxiv. · doi:10.1101/2020.11.02.363242
- Zhang, 2020, Ivermectin confers its cytotoxic effects by inducing AMPK/mTOR-mediated autophagy and DNA damage, Chemosphere, 259, 127448, 10.1016/j.chemosphere.2020.127448 · DOI
- Yang, 2020, The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer, Antivir. Res., 177, 104760, 10.1016/j.antiviral.2020.104760 · DOI · Paper page
- Wagstaff, 2012, Ivermectin is a specific inhibitor of importin alpha/beta-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem. J., 443, 851, 10.1042/BJ20120150 · DOI · Paper page
- Tay, 2013, Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin, Antivir. Res., 99, 301, 10.1016/j.antiviral.2013.06.002 · DOI · Paper page
- Gotz, 2016, Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import, Sci. Rep., 6, 23138, 10.1038/srep23138 · DOI · Paper page
- Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res., 178, 104787, 10.1016/j.antiviral.2020.104787 · DOI · Paper page
- Jans, 2019, Inhibitors of nuclear transport, Curr. Opin. Cell Biol, 58, 50, 10.1016/j.ceb.2019.01.001 · DOI
- Martin, A.J., and Jans, D.A. (2021). Antivirals that target the host IMPalpha/beta1-virus interface. Biochem. Soc. Trans. · DOI
- Joob, 2020, COVID-19 can present with a rash and be mistaken for dengue, J. Am. Acad. Dermatol., 82, e177, 10.1016/j.jaad.2020.03.036 · DOI · Paper page
- Kaddoura, 2020, COVID-19 Therapeutic Options Under Investigation, Front. Pharmacol., 11, 1196, 10.3389/fphar.2020.01196 · DOI
- Dingens, 2020, Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak, Nat. Commun., 11, 4378, 10.1038/s41467-020-18178-1 · DOI · Paper page
- Kaur, H., Shekhar, N., Sharma, S., Sarma, P., Prakash, A., and Medhi, B. (2021). Ivermectin as a potential drug for treatment of COVID-19: An in-sync review with clinical and computational attributes. Pharmacol. Rep. · DOI
- Thomas, 2021, Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial, JAMA Netw. Open, 4, e210369, 10.1001/jamanetworkopen.2021.0369 · DOI · Paper page
- Finzi, E., and Harrington, A. (2021). Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients. J. Med. Virol. · DOI
- DiNicolantonio, J.J., Barroso, J., and McCarty, M. (2020). Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. Open Heart, 7. · DOI
- Ahmed, 2021, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int. J. Infect. Dis., 103, 214, 10.1016/j.ijid.2020.11.191 · DOI · Paper page
- Navarro, 2020, Safety of high-dose ivermectin: A systematic review and meta-analysis, J. Antimicrob. Chemother., 75, 827, 10.1093/jac/dkz524 · DOI
- Kampf, G., Lemmen, S., and Suchomel, M. (2020). Ct values and infectivity of SARS-CoV-2 on surfaces. Lancet Infect. Dis. · DOI
- Alexander, J., Tinkov, A., Strand, T.A., Alehagen, U., Skalny, A., and Aaseth, J. (2020). Early Nutritional Interventions with Zinc, Selenium and Vitamin D for Raising Anti-Viral Resistance Against Progressive COVID-19. Nutrients, 12. · DOI · Paper page
- Noreen, S., Maqbool, I., and Madni, A. (2021). Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur. J. Pharmacol. · DOI · Paper page
- Hussein, 2021, Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19, J. Mol. Struct., 1231, 129979, 10.1016/j.molstruc.2021.129979 · DOI
- Westblade, 2020, SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19, Cancer Cell, 38, 661, 10.1016/j.ccell.2020.09.007 · DOI · Paper page
- Pujadas, 2020, SARS-CoV-2 viral load predicts COVID-19 mortality, Lancet Respir. Med., 8, e70, 10.1016/S2213-2600(20)30354-4 · DOI · Paper page
- Buonfrate, 2019, Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial, Lancet Infect. Dis., 19, 1181, 10.1016/S1473-3099(19)30289-0 · DOI · Paper page
- Rajter, 2021, Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study, Chest, 159, 85, 10.1016/j.chest.2020.10.009 · DOI · Paper page
- Gutierrez, 2008, Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats, Arzneimittelforschung, 58, 310
- Chaccour, C., Casellas, A., Blanco-Di Matteo, A., Pineda, I., Fernandez-Montero, A., Ruiz-Castillo, P., Richardson, M.A., Rodriguez-Mateos, M., Jordan-Iborra, C., and Brew, J. (2021). The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial. EClinicalMedicine, 100720. · DOI · Paper page
Cited by
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
Weibel, S., Popp, M., Reis, S., Skoetz, N., Garner, P., & Sydenham, E. (2023) · Research Synthesis Methods · doi:10.1002/jrsm.1599 · Cited by 93
Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
Hill, A., Mirchandani, M., & Pilkington, V. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab645 · Cited by 57
Zeraatkar, D., Pitre, T., Leung, G., Cusano, E., Agarwal, A., Khalid, F., Escamilla, Z., Cooper, M. A., Ghadimi, M., Wang, Y., et al. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2022-000309 · Cited by 44
Kataoka, Y., Banno, M., Tsujimoto, Y., Ariie, T., Taito, S., Suzuki, T., Oide, S., & Furukawa, T. A. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2022.06.015 · Cited by 44
Retracted
Metadata
- Authors
- Samaha, A., Mouawia, H., Fawaz, M., Hassan, H., Salami, A., Bazzal, A., Saab, H., Al-Wakeel, M., Alsaabi, A., Chouman, M., Moussawi, M., Ayoub, H., Raad, A., Hajjeh, O., Eid, A., & Raad, H.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2021-05-26
- Volume
- 13
- Issue
- 6
- Pages
- 989
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W3164155067
- Cited by
- 37
- References
- 2
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.